Boswellia and Improved Cognitive Function

Doses used in studies

g/day: 1.6 (median 1.6, IQR 1.6–1.6) — 1 study

Time to effect

Median: 4.2 months · IQR 4.2 months–4.2 months · Range 4.2 months–4.2 months — Reported in 1 of 1 study

1 of 1 paper

The clinical efficacy of Olibanum gum chewing in patients with Mild-to-Moderate Alzheimer disease: A randomized Parallel-Design controlled trial.

2023-12-08
RCT · n = 72
Neuropsychopharmacology reports 44(1)
- Fereshteh Ghorat
- Mahdi Sepidarkish
- Farzaneh Saadattalab
- Maedeh Rezghi
- Shamim Shahrestani
- Maryam Gholamalizadeh
- Saeid Doaei

PubMed: 38069542
DOI: 10.1002/npr2.12398

1 Insight on

Improved Cognitive Function

High evidence
Clinical

There was no significant difference between two groups regarding the improvements after the intervention (F = 0.157, p = 0.693). There were no significant differences between the groups for MMSE score after the intervention (F = 0.141, p = 0.708).

Effect: Neutral
Effect size: Small
Significant: No
Dose: 1.6 g/day